Literature DB >> 27832868

Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries.

Narcyz Ghinea1, Wendy Lipworth2, Richard Day3, Andrew Hill4, Gregory J Dore5, Mark Danta6.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27832868     DOI： 10.1016/S0140-6736(16)32051-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

1.  HCV elimination - lessons learned from a small Eurasian country, Georgia.

Authors:  Muazzam Nasrullah; David Sergeenko; Amiran Gamkrelidze; Francisco Averhoff
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-07-26       Impact factor: 46.802

2.  I (Don't) want to consume counterfeit medicines: exploratory study on the antecedents of consumer attitudes toward counterfeit medicines.

Authors:  Sylvester Senyo Ofori-Parku; Sung Eun Park
Journal:  BMC Public Health       Date:  2022-06-01       Impact factor: 4.135

Review 3.  Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?

Authors:  Madhumita Premkumar; Gagandeep S Grover; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2017-09-23

Review 4.  The Elimination of Hepatitis C as a Public Health Threat.

Authors:  Margaret Hellard; Sophia E Schroeder; Alisa Pedrana; Joseph Doyle; Campbell Aitken
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

5.  Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.

Authors:  Anita W M Suijkerbuijk; Albert Jan van Hoek; Jelle Koopsen; Robert A de Man; Marie-Josee J Mangen; Hester E de Melker; Johan J Polder; G Ardine de Wit; Irene K Veldhuijzen
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

6.  The complex legal and ethical issues related to generic medications. Viral hepatitis: a case study.

Authors:  M Danta; N Ghinea
Journal:  J Virus Erad       Date:  2017-04-01

7.  High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C.

Authors:  Andrew Hill; Giten Khwairakpam; James Wang; Sergey Golovin; Julia Dragunova; Rachel Smith; Vicky Houghton-Price; Roxanna Korologou-Linden; Sanjay Nath; Anna Savage; Greg Jefferys
Journal:  J Virus Erad       Date:  2017-10-01

8.  InterPrEP. Internet-based pre-exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients.

Authors:  Isaac Aloysius; Anna Savage; Jey Zdravkov; Roxanna Korologou-Linden; Andrew Hill; Rachel Smith; Vicky Houghton-Price; Marta Boffito; Nneka Nwokolo
Journal:  J Virus Erad       Date:  2017-10-01

9.  Pathways to ensure universal and affordable access to hepatitis C treatment.

Authors:  Caitlin H Douglass; Alisa Pedrana; Jeffrey V Lazarus; Ellen F M 't Hoen; Radi Hammad; Ricardo Baptista Leite; Andrew Hill; Margaret Hellard
Journal:  BMC Med       Date:  2018-10-09       Impact factor: 8.775

10.  Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study.

Authors:  Chen-Hua Liu; Yi-Jie Huang; Sien-Sing Yang; Chung-Hsin Chang; Sheng-Shun Yang; Hsin-Yun Sun; Chun-Jen Liu; Wen-Chun Liu; Tung-Hung Su; Hung-Chih Yang; Chun-Ming Hong; Tai-Chung Tseng; Pei-Jer Chen; Ding-Shinn Chen; Chien-Ching Hung; Jia-Horng Kao
Journal:  Sci Rep       Date:  2018-09-12       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.